Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Infiltrating Bladder Urothelial Carcinoma”

59 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 59 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07142200
What this trial is testing

A Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin Combined With PD-1 Inhibitor and Radiotherapy as Bladder-preserving Therapy in Patients With Localized HER2-high Expressing Muscle-invasive Bladder Urothelial Carcinoma Following Maximal Transurethral Resection

Who this might be right for
Bladder (Urothelial, Transitional Cell) Cancer
RenJi Hospital 45
Testing effectiveness (Phase 2)Study completedNCT03617913
What this trial is testing

Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer

Who this might be right for
Bladder Carcinoma Infiltrating the Muscle of the Bladder WallStage II Bladder Cancer AJCC v8Stage II Renal Pelvis Cancer AJCC v8+9 more
Mayo Clinic 2
Testing effectiveness (Phase 2)UnknownNCT05495724
What this trial is testing

Disitamab Vedotin Combined With Tislelizumab for Her2 Overexpressing High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable

Who this might be right for
Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
Tianjin Medical University Second Hospital 176
Testing effectiveness (Phase 2)Active Not RecruitingNCT03609216
What this trial is testing

Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

Who this might be right for
Infiltrating Bladder Urothelial CarcinomaStage II Bladder Urothelial CarcinomaStage III Bladder Urothelial Carcinoma
Alliance for Clinical Trials in Oncology 237
Testing effectiveness (Phase 2)Looking for participantsNCT06770582
What this trial is testing

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Who this might be right for
Non-Muscle Invasive Bladder Urothelial CarcinomaRecurrent Non-Muscle Invasive Bladder Urothelial CarcinomaStage I Bladder Cancer AJCC v8
National Cancer Institute (NCI) 160
Testing effectiveness (Phase 2)Active Not RecruitingNCT04164082
What this trial is testing

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Who this might be right for
Bladder Flat Urothelial Carcinoma In SituNon-Muscle Invasive Bladder Urothelial CarcinomaStage 0a Bladder Cancer AJCC v8+2 more
National Cancer Institute (NCI) 161
Early research (Phase 1)Looking for participantsNCT06766266
What this trial is testing

Irinotecan Liposomes Combined with Epirubicin in Recurrent Non-muscle Invasive Bladder Urothelium Carcinoma After Anthracyclines Treatment

Who this might be right for
Non-Muscle Invasive Bladder Urothelial Carcinoma
First Affiliated Hospital of Chongqing Medical University 18
Not applicableLooking for participantsNCT06396533
What this trial is testing

Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE)

Who this might be right for
Urothelial CarcinomaMuscle Invasive Bladder Urothelial CarcinomaNon-Muscle Invasive Bladder Urothelial Carcinoma
Fox Chase Cancer Center 92
Not applicableNot Yet RecruitingNCT05335512
What this trial is testing

Intravesical BCG: is the Urinary Bladder Ready to Receive it

Who this might be right for
Non-Invasive Bladder Urothelial Carcinoma
Tata Memorial Centre 100
Not applicableUnknownNCT05276167
What this trial is testing

Hyperthermic Intravesical Perfusion for Muscle-invasive Bladder Urothelial Carcinoma

Who this might be right for
High-Risk, Non-Muscle Invasive Bladder Urothelial CarcinomaPerfusion; ComplicationsIntraoperative Complications
Henan Cancer Hospital 40
Not applicableNot Yet RecruitingNCT07525349
What this trial is testing

Immune-Stromal Landscape in Muscle-Invasive Bladder Cancer

Who this might be right for
Muscle-Invasive Bladder CarcinomaUrothelial Carcinoma (UC)Bladder Cancer+2 more
Assiut University 100
Very early researchUnknownNCT06204614
What this trial is testing

Drug Screening Using IMD in Bladder Cancer

Who this might be right for
Muscle Invasive Bladder Urothelial Carcinoma
Brigham and Women's Hospital 18
Not applicableUnknownNCT04617743
What this trial is testing

The Effect of Post-voiding Reisdual Urine on Non-muscle Invasive Bladder Cancer Recurrence and Progression

Who this might be right for
Bladder Cancer RecurrentNon-Invasive Bladder Urothelial Carcinoma
Istanbul Medeniyet University 500
Early research (Phase 1)Looking for participantsNCT05843448
What this trial is testing

IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

Who this might be right for
High Risk Non-Muscle Invasive Bladder Urothelial CarcinomaStage 0a Bladder Cancer AJCC v8Stage 0is Bladder Cancer AJCC v8+1 more
University of California, Davis 30
Testing effectiveness (Phase 2)Ended earlyNCT03912818
What this trial is testing

Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

Who this might be right for
Bladder AdenocarcinomaBladder Mixed AdenocarcinomaBladder Squamous Cell Carcinoma+9 more
Stanford University 7
Testing effectiveness (Phase 2)UnknownNCT03549715
What this trial is testing

NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma

Who this might be right for
Infiltrating Bladder Urothelial Carcinoma
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie 121
Testing effectiveness (Phase 2)WithdrawnNCT03935347
What this trial is testing

Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy

Who this might be right for
Metastatic Bladder Urothelial CarcinomaMetastatic Renal Pelvis Urothelial CarcinomaMetastatic Ureter Urothelial Carcinoma+3 more
Roswell Park Cancer Institute
Not applicableLooking for participantsNCT06269536
What this trial is testing

Stress-reducing Intervention in Urothelial Carcinoma

Who this might be right for
Bladder Cancer
Comenius University 50
Testing effectiveness (Phase 2)Looking for participantsNCT06809140
What this trial is testing

Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer

Who this might be right for
Muscle Invasive Bladder Urothelial Carcinoma
Matthew Galsky 47
Very early researchActive Not RecruitingNCT02812420
What this trial is testing

Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery

Who this might be right for
HydronephrosisInfiltrating Bladder Urothelial Carcinoma Sarcomatoid VariantInfiltrating Bladder Urothelial Carcinoma, Micropapillary Variant+16 more
M.D. Anderson Cancer Center 54
Load More Results